In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Guidelines for Contributing Authors

 

In Vivo is the gold standard for analysis and expert thought leadership about the business of health care. Senior executives and strategists use it to anticipate industry trends, understand what’s happening beyond their areas of expertise and to identify risks and opportunities, new technologies and business models, novel deal structures and compelling leadership styles.

We welcome contributed articles from industry experts.

Here are some guidelines outlining what we’re looking for from contributors. We want to help you tailor your material most easily and efficiently to our audience’s needs, saving editorial time for you and us. Thank you in advance for your cooperation.

Our Readership

Many of our subscribers are in biopharmaceutical, medical device and diagnostics companies. Our biggest subscriber bases are:

  • the senior executive C-suites
  • business development, commercial and corporate planning
  • senior marketing, including market access
  • senior R&D management

We are also well read by service providers, including health care investment bankers, equity research groups, venture capitalists and major life sciences consulting firms. We do not reach bench-level research or clinical development teams, individual product managers or sales, manufacturing or engineering staff.

Crafting The Story

First and foremost, we are looking for a clear, concise and compelling “so what” to any piece of material.

  • Why will our readers be interested in what you write?
  • What actions should they take based on your article?

We would appreciate a short one- or two-sentence summary of the so-what at the top of the submission.

Remember that our readers are experienced industry executives. Thus we rarely find general “state of the industry” overview pieces helpful. That’s not to say we reject trend pieces; they must simply be focused on a particular, well-defined and clearly exemplified trend; and in particular a trend our writers and contributors haven’t yet noticed or on which you take an unusual stance or from which you draw unusual implications. Stories that feature original research are of particular interest. An informed opinion can bring an additional element of originality to a story as well.

We do seek concrete examples and illustrations of points made or trends highlighted. Which company tried this, did it work? Who is trying it now? Specifics – company and product examples, well-vetted and independently derived statistics – are of far more value to our readers than abstract descriptions or theoretical analyses without any proof of their use in the real world. Examples needn’t – and we know often can’t – include real names. Using generic descriptions – for example, "a big pharma" or "a biotech firm" – is often sufficient, granted, of course, the story is true and specific. This will not only be more useful to our readers, it will also provide credibility: this contributor’s idea is already being tried out.

Please include quotations from other people. Additional voices and perspectives always enhance articles.

Break out relevant subtopics as sidebars or boxes – that will improve the way the story looks and reads.

If you don't have access to In Vivo, we are happy to send you some recent articles so you can familiarize yourself with our format and level of coverage.

Article Length

In Vivo feature articles are typically 2,000 to 3,000 words long. Shorter articles and opinion pieces run between 750 and 1,500 words.

Format

Bullets: In addition to the two-sentence so-what mentioned above, In Vivo features must also include three to four bullet points that identify the main themes of your article. Shorter articles also require a two-sentence summary, but not bullet points.

Intro: For feature-length articles, we require four to five paragraphs of introductory text presenting the issue and argument, and broadly scoping the piece before you dive into the heart of the matter.

Subheads: Subheads should be included at four- to eight- paragraph intervals, breaking the piece into logical subtopics.

Graphics: We encourage the use of charts, other graphic material and/or text boxes that advance the story where appropriate. All should be clearly labeled and sourced. If you have submitted graphics to accompany your story, we will need original source files (xls, ppt, pdf), rather than mere images pasted into your Word document. Our in-house designers will modify the appearance of your graphics to match In Vivo's style. If we make substantive edits to exhibits we will discuss them with you.

Bylines and bios: We will run a brief bio note at the end of the article. Please provide names, email addresses and job titles for all bylined authors.

Submission Process

First, discuss the basic idea of the article with an In Vivo editor who will determine if the story is a good fit for us and decide which of our editors is best for you to work with. Then, rather than writing an entire article only to find that we can't use it, submit a bulleted outline (either in an email or Microsoft Word document), starting at the top with the so-what described above and then list four or five key points outlining the essential elements of the argument. Your editor will then reach out to you with any comments and suggestions. At that point you should feel free to start writing the piece.

Please file your draft story as a plain MS Word document (no company templates, please). In Vivo cannot accommodate complex formatting or footnotes. If you want to cite a specific source for a fact, please incorporate it into the text of the story.

When you file your draft, we will edit it and send our comments back to you. Once all parties are satisfied with the story, we will send it through internal editing and proofing. It's unlikely there will be substantive changes to the content at this point. If there are, we will let you know. We won't inform you about minor, stylistic changes.

Note that it generally takes six to eight weeks between the time you file your draft to the time the story is ready to post.

Posting, Publishing and Promotion

If your article is scheduled to appear in a monthly print issue, we will send you a proof to review prior to publication. Once the article posts and publishes, we will send you a magazine-quality pdf for your internal use. Our sales team is always happy to discuss reprint/reposting rights if you'd like to distribute the piece to a broader audience. In Vivo owns the copyright to everything we publish. Once your story posts online, we will promote it via email alerts, Twitter and other social media. We encourage you to do the same.

Questions? Please contact In Vivo's managing editor Nancy Dvorin (nancy.dvorin@informa.com).

 

UsernamePublicRestriction

Register

Advertisement